Stille AB (STIL) AI Stock Analysis

• Market Cap: kr1.59B
• Dividend Yield: N/A
• Average Volume (3M): 6.57K
• Price to Earnings (P/E): 39.3
• Beta (1Y): 0.47
• Revenue Growth: 13.36%
• EPS Growth: -20.56%
• Country: SE
• Employees: 162
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.89
• Shares Outstanding: 8,985,447
• 10 Day Avg. Volume: 9,615
• 30 Day Avg. Volume: 6,571
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: kr239.00 ▲(35.80% Upside)

Stille AB's strong financial performance is the primary driver of its stock score, supported by robust revenue growth and cash flow generation. However, technical indicators suggest bearish momentum, and the valuation appears high, limiting the overall score.

Stille AB Business Overview & Revenue Model

Company Description

Stille AB (STIL) is a Swedish company specializing in the development and manufacturing of high-quality surgical instruments and equipment for the healthcare sector. Founded in 1841, Stille has a long history of innovation and expertise in surgical solutions. The company primarily operates in the medical technology sector, focusing on advanced surgical instruments for various specialties, including orthopedics, general surgery, and minimally invasive procedures. Stille's core products include surgical scissors, forceps, and specialized instruments designed to enhance the precision and efficiency of surgical procedures.

How the Company Makes Money

Stille AB generates revenue through the sale of its surgical instruments and equipment to hospitals, clinics, and healthcare professionals worldwide. The company operates a direct sales model as well as partnerships with distributors to reach a broader market. Key revenue streams include the sale of standard surgical instruments, custom-designed instruments tailored to specific surgical needs, and ongoing maintenance and support services for its products. Additionally, Stille may engage in collaborations with healthcare providers for research and development purposes, which can lead to new product innovations and further enhance its market presence. The company's focus on quality and innovation allows it to maintain a competitive edge and sustain its revenue growth.

Stille AB Financial Statement Overview

Summary

Stille AB exhibits strong financial performance with robust revenue growth, efficient operations, and a solid balance sheet. The company's ability to generate cash flow is a key strength, providing flexibility for strategic initiatives. While profitability metrics are strong, there is potential for further improvement in net profit margins to align with industry leaders.

Income Statement

Stille AB demonstrates strong revenue growth with a 16.93% increase in the latest year, supported by healthy gross and net profit margins of 51.87% and 10.21%, respectively. The EBIT and EBITDA margins are robust at 14.87% and 20.87%, indicating efficient operational management. However, the net profit margin shows room for improvement compared to industry leaders.

Balance Sheet

The company's balance sheet is solid, with a low debt-to-equity ratio of 0.09, reflecting prudent financial leverage. The return on equity is moderate at 8.32%, suggesting potential for higher profitability. The equity ratio of 69.87% indicates a strong equity base, enhancing financial stability.

Cash Flow

Stille AB's cash flow performance is impressive, with a significant free cash flow growth rate of 217.02%. The operating cash flow to net income ratio of 0.54 and free cash flow to net income ratio of 0.81 highlight effective cash generation relative to earnings. This strong cash flow position supports future investments and debt servicing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	541.65M	569.95M	294.89M	246.35M	187.09M	142.63M
Gross Profit	288.43M	295.64M	132.17M	111.57M	83.46M	57.43M
EBITDA	90.20M	118.97M	56.04M	44.78M	28.89M	15.68M
Net Income	52.21M	58.21M	26.65M	27.32M	16.10M	8.27M
Balance Sheet
Total Assets	959.54M	1.00B	804.89M	342.55M	308.85M	164.90M
Cash, Cash Equivalents and Short-Term Investments	164.51M	158.49M	241.45M	36.68M	27.80M	38.12M
Total Debt	0.00	63.09M	62.94M	70.77M	81.48M	24.10M
Total Liabilities	259.77M	301.70M	172.64M	152.74M	160.75M	53.85M
Stockholders Equity	699.76M	699.40M	632.25M	189.81M	148.10M	111.05M
Cash Flow
Free Cash Flow	77.99M	59.24M	24.37M	23.89M	-11.74M	-2.89M
Operating Cash Flow	94.05M	73.53M	37.28M	31.94M	7.28M	20.56M
Investing Cash Flow	1.86M	-330.31M	-12.90M	-8.04M	-51.90M	-23.44M
Financing Cash Flow	-26.26M	171.40M	178.99M	-18.54M	33.22M	-2.75M

Stille AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 176.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STIL, the sentiment is Negative. The current price of 176 is below the 20-day moving average (MA) of 189.55, below the 50-day MA of 205.19, and below the 200-day MA of 218.77, indicating a bearish trend. The MACD of -7.63 indicates Positive momentum. The RSI at 27.43 is Positive, neither overbought nor oversold. The STOCH value of 9.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:STIL.

Stille AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STIL	66 Neutral	kr1.59B	39.25	―	―	13.36%	-20.56%
CRAD.B	64 Neutral	€1.11B	47.83	6.93%	―	-5.80%	-65.99%
PAX	57 Neutral	$1.54B	138.75	2.64%	―	14.28%	-68.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSSD	50 Neutral	kr1.23B	-24.30	―	―	38.43%	57.76%
SEZI	44 Neutral	$883.55M	-6.48	-36.55%	―	62.24%	21.16%
SEDANA	43 Neutral	€1.00B	-24.63	-4.42%	―	13.48%	28.98%